What is DMT and how is it used in therapy?

DMT (N,N-dimethyltryptamine) is a naturally occurring psychedelic compound found in many plants and produced endogenously in small amounts in the human body. When inhaled or injected, it produces an extremely rapid and intensely visionary psychedelic experience lasting 10-20 minutes. When taken orally as ayahuasca (combined with MAO inhibitors in a plant brew), it produces an experience lasting 4-6 hours. DMT has not entered the formal pharmaceutical development pipeline the way psilocybin or MDMA have, but Imperial College London has developed a novel approach: IV DMT infusion ('DMTx') that can sustain the experience for a controllable duration — from minutes to hours — opening the possibility of extended psychedelic therapeutic sessions. This is among the most scientifically ambitious psychedelic research of the 2020s.

What is DMTx and how does the IV DMT research work?

DMTx is a technique developed at Imperial College London (primarily by Chris Timmermann and Robin Carhart-Harris's team) for administering N,N-DMT intravenously in a continuous, titrated infusion. Rather than the abrupt 10-15 minute 'flash' of smoked DMT, IV infusion allows researchers to precisely control the onset, depth, and duration of the experience — maintaining a stable DMT state for 20 minutes, 1 hour, or longer as needed. The 2023 Phase 1 Imperial study (Timmermann et al.) successfully demonstrated that IV DMT is safe and produces a sustained, controllable psychedelic experience. Participants reported sustained visual and existential experiences without the overwhelming abruptness of smoked DMT. The technique allows session-length therapeutic work to occur within the DMT space — something previously impossible given DMT's inherent brevity.

What is the difference between N,N-DMT and 5-MeO-DMT?

N,N-DMT and 5-MeO-DMT are related but pharmacologically and experientially distinct compounds. N,N-DMT: rich, complex visionary experience — geometric patterns, entities, narrative voyages to what users describe as other realms. Primarily 5-HT2A agonism. In ayahuasca (oral), lasts 4-6 hours. Smoked/inhaled, lasts 10-15 minutes. Found in many plants (Psychotria viridis, Mimosa hostilis, etc.) and in some plant brews. 5-MeO-DMT: ego dissolution experience — oceanic boundlessness, unity consciousness, minimal visual content. Primarily 5-HT1A + 5-HT2A agonism. Lasts 15-30 minutes. Found in Sonoran Desert toad venom and some plants; also synthesized. The experiential character is fundamentally different: N,N-DMT tends to produce a journey through elaborate inner worlds; 5-MeO-DMT tends to produce the dissolution of the inner world entirely.

Is DMT being studied for depression or PTSD?

Yes — multiple programs are emerging. Imperial College London's DMTx research has expanded to investigate the extended-state technique for treatment-resistant depression and existential distress. Small Tree Pharma (formerly known as GH Research-adjacent programs) is advancing injectable DMT formulations. The Small Tree / GH Research Comb. program has been running Phase 1/2 studies of IV DMT. Ayahuasca's DMT component, studied as a full brew at sites in Brazil, Switzerland, and Canada, has published positive preliminary data for depression and PTSD (União do Vegetal-affiliated research). The depression mechanism is plausible: N,N-DMT is a strong 5-HT2A agonist, producing the default mode network disruption and neuroplasticity associated with antidepressant effects of psilocybin and LSD.

Is DMT legal? Can I access DMT therapy?

N,N-DMT is Schedule I in the United States. Unlike psilocybin (legal in Oregon and Colorado service centers) or 5-MeO-DMT (included in Colorado's Prop 122), N,N-DMT is not included in any state regulatory framework as of 2026. Ayahuasca — a brew containing DMT — can be accessed legally in some contexts: (1) Religious exemptions under RFRA for established religious organizations like União do Vegetal (UDV) and Santo Daime, who have won court cases protecting their ceremonial use. (2) Peru, Brazil, and Jamaica, where ayahuasca is either legal or unscheduled. (3) Clinical trials — Imperial College London's DMTx research and other trials provide authorized access under IND. Colorado's Prop 122 includes DMT in its natural medicine framework — as of 2026, the regulations for DMT-containing plants in CO are still being finalized.

DMT Therapy Research 2026 — IV DMT, DMTx, Clinical Trials & Oracle Predictions

DMTx

Imperial College's IV infusion technique — controllable duration from minutes to hours

10-15

Minutes — typical inhaled DMT duration (without IV infusion)

First US state to include DMT in a natural medicine regulatory framework (Prop 122)

1955

Year DMT's psychoactive properties were first described (Stephen Szara, Hungary)

18%

Oracle: FDA approval for an IV DMT program by 2030

N,N-DMT: Understanding the Compound

N,N-dimethyltryptamine (DMT) is one of the most widely distributed psychedelic compounds in nature — found in hundreds of plant species and produced endogenously in the human body (detected in the pineal gland, retina, blood, and cerebrospinal fluid, though its physiological role remains debated). It is structurally a tryptamine, closely related to serotonin (5-HT) and psilocin (the active form of psilocybin).

DMT's psychedelic effects are mediated primarily through 5-HT2A receptor agonism — the same mechanism as psilocybin and LSD. But its subjective character is dramatically different from other psychedelics: DMT is characterized by extraordinarily rapid onset (seconds when inhaled or injected), extreme visual intensity, and a unique phenomenon that distinguishes it from all other psychedelics in the literature — entity encounters.

The Entity Phenomenon

Across cultures, across centuries, across individuals with no prior knowledge of DMT pharmacology, users of DMT report encounters with non-human beings: autonomous entities described variously as elves, aliens, spirits, guides, jesters, and presences of profound intelligence. The prevalence, consistency, and cross-cultural recurrence of this phenomenon is one of the most studied and debated phenomena in psychedelic neuroscience.

A landmark 2020 survey by Davis et al. (Journal of Psychopharmacology, n=2,561 DMT users) found: 45% reported entity encounters; of those, 41% described entities as "beings of light," 39% as gnomes/elves/fairies, 38% as "alien-like," and 27% as human-like. Remarkably, 58% of respondents who had never believed in entities/spirits prior to their DMT experience came to believe in them afterward. The ontological implications — and the neurological substrate — of these experiences are active research questions at Imperial College and elsewhere.

DMTx: The Imperial College Breakthrough

The fundamental problem with DMT as a therapeutic agent has always been time. A smoked DMT experience lasts 10-15 minutes — not enough time for the therapeutic processing that psilocybin researchers do over 4-6 hours, or that MDMA researchers do over 8 hours. You can't do meaningful trauma therapy in 10 minutes.

The DMTx technique solves this. Developed by Chris Timmermann (now at Harvard) and the Imperial College psychedelic research group, DMTx administers N,N-DMT via continuous IV infusion at a precisely controlled rate, maintaining a stable plasma concentration and sustained psychedelic state for a programmable duration.

Feature	Smoked/Inhaled DMT	DMTx (IV Infusion)
Onset	30-60 seconds	Gradual (controlled)
Duration	10-15 minutes	Controllable — 20 min to 4+ hours
Depth control	None after administration	Precise — titrate infusion rate
Therapeutic processing window	None	Full session available
Research feasibility	Limited — too brief for most interventions	Full clinical trial design possible
Safety monitoring	Difficult during rapid experience	Medical monitoring possible throughout
Intensity	Very high — abrupt onset	Manageable — controlled ramp-up

Phase 1 Results (Timmermann et al., 2023)

The 2023 Imperial Phase 1 publication in Neuropsychopharmacology (n=11 healthy volunteers) established proof-of-concept for DMTx:

Finding	Detail
Safety	No serious adverse events. Transient elevations in heart rate and blood pressure during infusion, returning to baseline after termination.
Controllability	Dose-response confirmed — infusion rate correlated with subjective intensity and EEG changes. Experience could be dialed up or down.
Duration	Successfully maintained participants in a stable DMT state for up to 60 minutes.
Entity encounters	9 of 11 participants reported entity encounters during extended DMT state.
Phenomenology	Participants described sustained, narrative psychedelic experiences — comparable to what users describe with longer-acting psychedelics, but within the DMT phenomenological space.
EEG	Characteristic delta/theta wave increases + alpha suppression during infusion — matching fMRI findings from smoked DMT, now sustained and measurable.

Why this matters: DMTx is the first technique that makes DMT-assisted therapy practically feasible. It also opens a unique research window — the ability to study what happens neurologically during a sustained DMT experience, with real-time EEG and fMRI, while maintaining conversation with the participant. This has no equivalent in the history of psychedelic research.

DMT Access Routes: A Comparison

Inhaled / Smoked N,N-DMT

Duration 10-15 minutes

Onset 30-60 seconds — very abrupt

Legal (US) Schedule I — no legal access outside trials

Experience type Very intense visionary experience — entities, geometry, "other realms"

Therapeutic value Limited by brevity — hard to do in-session therapeutic work

Oral DMT (Ayahuasca brew)

Duration 4-6 hours

Onset 30-60 minutes (oral, slower)

Legal (US) RFRA exemptions for religious orgs (UDV, Santo Daime); Peru/Jamaica/Brazil legal

Experience type Visionary, narrative, often emotionally intense — more processable than smoked DMT

Therapeutic value Full therapeutic window — established ceremonial and clinical tradition

Route	Duration	DMT Form	MAOI Required?	Legal US Access	Clinical Research
Inhaled/smoked	10-15 min	Freebase DMT (pure)	No	No (Schedule I)	Limited by brevity
IV infusion (DMTx)	Controllable	DMT fumarate or tartrate	No	Trial only (IND)	Imperial Phase 1/2 active
Oral (ayahuasca)	4-6 hours	DMT in plant matrix	Yes (β-carbolines)	RFRA religious exemption (UDV, Santo Daime)	Multiple observational + RCT studies
IM injection	20-45 min	DMT salt	No	No (Schedule I)	Rick Strassman's 1990s research (foundational)

DMT vs. 5-MeO-DMT: Which Is Which?

These two compounds are frequently confused by name but produce dramatically different experiences and have different pharmacological profiles.

Feature	N,N-DMT (This Page)	5-MeO-DMT
Full name	N,N-dimethyltryptamine	5-methoxy-N,N-dimethyltryptamine
Primary mechanism	5-HT2A agonism (primarily)	5-HT1A + 5-HT2A agonism
Experience type	Rich visual content, entities, narrative voyages	Ego dissolution, oceanic boundlessness — minimal visual content
Duration (inhaled)	10-15 min	15-30 min
Sources	Hundreds of plant species, ayahuasca, human body	Sonoran Desert toad, some plants, synthetic
CO Prop 122	Yes — included	Yes — included
Clinical stage	Phase 1 (DMTx) / ayahuasca observational	Phase 2 (Hopkins)
Entity encounters	Very common — 45% in surveys	Uncommon — primarily non-visual

Active DMT Research Programs (June 2026)

Institution	Program	Status	Notes
Imperial College London	DMTx Phase 2 for Treatment-Resistant Depression	Active	Following successful Phase 1 (2023). Building on the controlled IV infusion technique. EEG + fMRI neuroimaging concurrent.
Harvard (Timmermann)	DMT phenomenology + entity research	Active	Chris Timmermann moved from Imperial to Harvard; continuing DMTx research with expanded scope.
Beckley Foundation (UK)	DMT neuroimaging	Active	Foundational brain imaging studies of DMT's neural correlates.
Associação Beneficente União do Vegetal (UDV)	Ayahuasca observational + RCT studies	Ongoing	UDV's decades of ceremonial data generating research. Brazilian academic partnerships active.
ICEERS Foundation (Spain)	Ayahuasca harm reduction + outcomes	Ongoing	International Center for Ethnobotanical Education, Research, and Service — ayahuasca outcomes database.
Hebrew University of Jerusalem	DMT synthesis + endogenous DMT role	Active	Investigating DMT's role as an endogenous compound — theoretical but potentially foundational for understanding its therapeutic mechanism.

Ayahuasca vs. IV DMT: Which Is Closer to Approval?

Ayahuasca (oral DMT combined with MAOI-containing plants) has a longer history of controlled research and a substantial observational evidence base. The Federação Espírita Beneficente União do Vegetal (UDV) in Brazil has maintained decades of records. Academic studies from Brazil, Spain, and Canada have shown antidepressant and anti-addiction effects in observational and small RCT designs. The Amazon Research Biobank and ICEERS are building the largest systematic dataset.

However, ayahuasca's regulatory path to FDA approval is complex: it is a multi-compound brew, not a single purified molecule. The FDA approves specific chemical entities, not traditional plant preparations. Standardizing an ayahuasca brew (variable alkaloid content across preparations, from different plant sources) for a Phase 3 trial is a significant pharmaceutical challenge that has slowed development. A standardized oral DMT formulation with known MAO inhibitor ratios is theoretically possible but not yet in late-stage development.

IV DMT (DMTx) sidesteps the ayahuasca preparation problem entirely — it uses a purified, precisely dosed pharmaceutical compound. This makes it the more tractable path to FDA approval, even though ayahuasca has more naturalistic evidence.

Oracle Predictions: DMT Regulatory Trajectory

18%

FDA approval of any IV DMT program (DMTx) for TRD by 2030

44%

DMTx Phase 2 TRD trial reports positive results by 2027

61%

Colorado Prop 122 includes functioning DMT service center access by 2028

35%

A pharmaceutical company files IND for a standardized oral DMT (ayahuasca-analog) formulation by 2028

27%

Federal court ruling expands RFRA ayahuasca exemptions to additional religious or ceremonial contexts by 2028

72%

DMTx enters Phase 3 clinical trials (for TRD, depression, or existential distress) by 2029

Agent Perspectives

Neuropharmacologist

"The DMTx technique is genuinely unprecedented. For the first time we can study what is happening neurologically during a sustained DMT experience — in real time, with fMRI, with the participant able to communicate. The 2023 Phase 1 EEG data is extraordinary: you can literally watch the neural correlates of entity contact in real time. I don't say that to suggest anything metaphysical — I say it because the consistent neural signatures associated with entity encounters across subjects are one of the most interesting data sets in consciousness research. Whatever is happening is systematic and measurable."

FDA Regulatory Analyst

"IV DMT is an early-stage development program. Phase 1 safety — good. Phase 2 efficacy — pending. Realistically, FDA approval for any DMT program is a 2030s story at the earliest, unless they fast-track behind psilocybin's approval pathway. The BTD argument would be the same — TRD with no available therapy — but they'd need to show Phase 2 data that justifies fast-tracking. The DMTx duration-control innovation is fascinating from a pharmacology standpoint. Whether it translates to better outcomes than psilocybin is the key clinical question."

Investigative Journalist

"The entity research is going to be the most culturally impactful psychedelics story of the next decade. When major academic institutions publish peer-reviewed research describing the consistent neurological signatures of entity contact experiences — and this research is now happening at Harvard and Imperial — it will force a serious cultural conversation about consciousness, experience, and what the brain is actually doing in these states. The entity research isn't separate from the therapeutic research; the same participants who report healing from DMT often attribute it specifically to what they learned from entities they encountered. Treating this as a confound rather than a mechanism is increasingly scientifically indefensible."

Ayahuasca Researcher

"I want to gently push back on the idea that IV DMT is simply 'better' than ayahuasca for therapeutic purposes. Ayahuasca's MAOI component has its own pharmacological contributions — harmaline and harmine have MAOI activity, mild psychedelic properties, and neuroplasticity effects. The full brew may have therapeutic properties beyond the DMT component alone. The plant medicine tradition's 4-6 hour experience, with its narrative arc and integration window built in, has 3,000 years of empirical refinement behind it. IV DMT is scientifically tractable and exciting. But we should be careful about assuming the pharmaceutical-pure version will always outperform the traditional context."

Frequently Asked Questions

N,N-DMT (dimethyltryptamine) is a naturally occurring psychedelic found in hundreds of plants and produced by the human body. When inhaled, it produces a 10-15 minute intensely visionary experience; in ayahuasca (oral, with MAOI plants), 4-6 hours. Imperial College London's DMTx technique administers DMT via continuous IV infusion, sustaining a controllable extended state — opening the possibility of therapeutic work within the DMT experience. The 2023 Phase 1 confirmed safety; Phase 2 for depression is active. Ayahuasca research (oral DMT) has been ongoing in Brazil, Spain, and Canada for decades with positive preliminary evidence for depression and addiction.

DMTx is Imperial College London's IV infusion technique for N,N-DMT. By continuously infusing DMT intravenously at a controlled rate, researchers can maintain a stable psychedelic state for a programmable duration — from 20 minutes to hours. This solves DMT's fundamental limitation as a therapeutic agent (too brief for in-session therapy). The 2023 Phase 1 (n=11) demonstrated safety, controllability, and that participants can communicate and engage therapeutically during a sustained DMT state. Phase 2 for treatment-resistant depression is now active.

Both are tryptamine psychedelics but with fundamentally different experience profiles. N,N-DMT produces rich, complex visionary content — geometric patterns, entities, "other worlds" — primarily via 5-HT2A agonism. 5-MeO-DMT produces ego dissolution and oceanic boundlessness with minimal visual content — primarily via 5-HT1A + 5-HT2A agonism. N,N-DMT is the active compound in ayahuasca; 5-MeO-DMT is the compound in Sonoran Desert toad venom. Colorado's Prop 122 includes both. Their therapeutic applications and mechanism stories are distinct.

Yes. Imperial College London's DMTx program is in Phase 2 for treatment-resistant depression. Ayahuasca observational studies from Brazil and Spain have shown antidepressant effects. The PTSD evidence for DMT specifically is more limited — MDMA has the leading evidence for PTSD. However, the mechanism of DMT (5-HT2A agonism, DMN disruption, neuroplasticity) is the same mechanism implicated in psilocybin's antidepressant effect, so the theoretical basis for antidepressant activity is strong. Clinical evidence is early-stage relative to psilocybin.

N,N-DMT is Schedule I in the US. Legal access options: (1) Clinical trials (ClinicalTrials.gov — search "DMT" for active studies). (2) Ayahuasca via RFRA religious exemption — the UDV and Santo Daime have court-established rights to use ayahuasca in their ceremonies in the US. (3) Colorado's Prop 122 includes DMT in its natural medicine framework — regulations for DMT-containing plant access are under development. (4) International — ayahuasca ceremonies in Peru, Brazil, and Jamaica. (5) Netherlands — ayahuasca occupies a legal grey area (plant status). Schedule I means no commercial therapeutic access in the US outside of these pathways.

Related Research

🔮 OOTWOracle tracks DMT and DMTx research daily

8 AI agents monitoring Imperial trial registrations, pharma filings, congressional DMT legislation, and the evolving ayahuasca legal landscape — providing daily confidence-scored predictions on every psychedelic's regulatory trajectory.

View Today's Oracle Report →

DMT Therapy Research 2026: IV DMT, DMTx & the Clinical Frontier